File contents:
A. Modelled scenarios
B. Results codebook
C. Citation

*** A. Modelled scenarios ***
7 scenarios were modelled: a baseline scenario of no scale-up, and six different packages of scale-up in which we improved the availability of imaging or treatment modalities and 
quality of care to the mean level of high-income countries. Scenario names are used as prefixes for each results file.  

|Scenario         |Description                                                                                                                                                     |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
|Baseline         |[No scale-up]                                                                                                                                                   |
|Imaging          |Scale-up of all imaging modalities (ultrasound, x-ray, CT, MRI, PET, SPECT)                                                                                     |
|Treatment        |Scale-up of all treatment modalities (chemotherapy, radiotherapy, surgery, targeted therapy)                                                                    |
|Quality          |Scale-up of quality of care                                                                                                                                     |
|Treatment_Quality|Scale-up of all treatment modalities and quality of care                                                                                                        |
|Trad_CT_Quality  |Scale-up of traditional treatment modalities (chemotherapy, surgery, radiotherapy) and imaging modalities (ultrasound, x-ray), as well as CT and quality of care|
|Comprehensive    |Scale-up of all imaging and treatment modalities and quality of care                                                                                            |

*** B. Results codebook ***
Estimated lifetime health and economic costs/benefits for patients diagnosed with one of 11 cancers (oesophagus, stomach, colon, rectum, anus, liver, pancreas, lung, breast, 
cervix uteri, and prostate) between 2020-2030 (inclusive).

|File               |Contents                      |
|-------------------|------------------------------|
|[scenario]_Mean.csv|Estimated indicators - mean   |
|[scenario]_LB.csv  |Estimated indicators - 95% LB |
|[scenario]_UB.csv  |Estimated indicators - 95% UB |

Column headers

|Column Label      |Column Index|Description                                                                          |
|------------------|------------|-------------------------------------------------------------------------------------|
|name              |           0|Name of geographic area                                                              |
|ISOCode           |           1|Country code  (ISO-3)                                                                |
|cancerDeaths      |           2|Cancer deaths, all 11 cancers combined                                               |
|lifeyears         |           3|Lifeyears for cancer patients                                                        |
|lifeyearsDis      |           4|Lifeyears for cancer patients, discounted (3%)                                       |
|costs             |           5|Cancer treatment costs                                                               |
|costsDis          |           6|Cancer treatment costs, discounted (3%)                                              |
|benefitsFI        |           7|Lifetime economic benefits - full income appproach                                   |
|benefitsFIdis     |           8|Lifetime economic benefits - full income appproach, discounted (3%)                  |
|benefitsHC        |           9|Lifetime economic benefits - human capital appproach                                 |
|benefitsHCdis     |          10|Lifetime economic benefits - human capital appproach, discounted (3%)                |
|netFI             |          11|Net benefits, compared to Baseline - full income appproach                           |
|netFIdis          |          12|Net benefits, compared to Baseline - full income appproach, discounted (3%)          |
|netHC             |          13|Net benefits, compared to Baseline - human capital appproach                         |
|netHCdis          |          14|Net benefits, compared to Baseline - human capital appproach, discounted (3%)        |
|roiFI             |          15|Return on investment, compared to Baseline - full income appproach                   |
|roiFIdis          |          16|Return on investment, compared to Baseline - full income appproach, discounted (3%)  |
|roiHC             |          17|Return on investment, compared to Baseline - human capital appproach                 |
|roiHCdis          |          18|Return on investment, compared to Baseline - human capital appproach, discounted (3%)|

*** C. Citation ***
Ward ZJ, Scott AM, Hricak H, Atun R.
Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis.
Lancet Oncol 2021; In press.